Company Description
GW Pharmaceuticals PLC. The Group's principal activity is developing a range of new medicines based on cannabis and other controlled drugs. The Group's lead programme is the development of a portfolio of cannabinoid medicines, including Sativex, to ...
More
Related Business Topics
Breaking News
Reuters UK - 8 hours ago
Pharma posts FY profit Reuters adsrc 'reuters.co.uk/finance/deals/regulatory/article;' ( typeof(AD_TRACKER) 'undefined' AD_TRACKER.globalAdSrcType null ) ((typeof (hideAllAds) 'undefined' hideAllAds false) (typeof (AD_TRACKER) 'undefined' ...
Forbes.com - 8 hours ago
* Says Bayer to pay 10 mln stg after UK approval of Sativex * Sees becoming commercial-stage pharma company in 2010 * FY pretax profit 1.2 mln stg vs 10.2 mln stg loss (Adds details) Nov 25 (Reuters) - Britain's GW Pharmaceuticals swung to its first ...
Reuters - 9 hours ago
Pharma posts FY profit Reuters adsrc 'reuters.com.dart/bizfinance/markets/news/article;' ( typeof(AD_TRACKER) 'undefined' AD_TRACKER.globalAdSrcType null ) if Unleashed on Reuters Blogging the financial meltdown adsrc ...
